LAZORR Binds Six Pharma Rivals In India With Goals Of Operational Excellence And Cost Control
This article was originally published in PharmAsia News
Increasing competition from China has Indian pharmas banding together to share best practices.
You may also be interested in...
Translational R&D Models Like Precompetitive Alliances Needed To Energize Drug Discovery - Indian Symposium
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.